What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-03-30 compared with 2025-03-31 · 29 added, 49 removed, 4 unchanged (95% of the section changed)

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market for Registrant’s Common Equity,

Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our Common Stock is quoted on the OTC Pink under the symbol “GEVI.” Our stock is thinly traded on the OTC Markets and there can be no assurance that a liquid market for our common stock will ever develop.

For the periods indicated, the following table sets forth the high and low bid prices per share of common stock based on inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

Fiscal Year 2024

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Fiscal Year 2023

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Our Common Stock began trading on the NYSE American

on December 4, 2025, under the trading symbol “CITR”.

Security Holders

As of March 21, 2025, we estimate there were approximately 750 holders of record and 52,378,201 shares of our Common Stock were issued and outstanding.

As of March 30, 2026, we estimate there were approximately

745 holders of record and 19,150,234 shares of our Common Stock were issued and outstanding.

Dividend Policy

We have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings (if any) will be retained for the development of our business and no dividends will be declared or paid on our common stock.

Any future dividends on our common stock will be subject to the discretion of our board of directors and will depend upon, among other things, our earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent facts.

We have not paid any dividends on our common stock

since inception and we currently expect that, in the foreseeable future, all earnings (if any) will be retained for the development of

our business and no dividends will be declared or paid on our common stock.

Any future dividends on our common stock will be subject to

the discretion of our board of directors and will depend upon, among other things, our earnings (if any), operating results, financial

condition and capital requirements, general business conditions and other pertinent facts.

Securities Authorized for Issuance under

Equity Compensation Plans

The information required by Item 5 of Form 10-K regarding

equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

Recent Sales of Unregistered Securities

During the past two years, we completed the following transactions in reliance upon exemptions from registration under the Securities Act:

Between September 27, 2023, and March 21, 2025, we issued 1,001,969 shares of Series C Convertible Preferred Stock.

The following table summarizes the offering, including the number of shares sold and the amount raised.

The proceeds were used for general working capital and operational purposes, including Legal Fees, Accounting and Audit Fees, testing and certification, and preparation to launch product offerings.

Shares Issued

Alta Investments LLC

Robert Dailey

FEC Investments LLC

East Shore Industries LLC

Gerald Yanowitz

Joel Yanowitz and Amy Metzenbaum Revocable Trust

Super Eight Capital Holding Ltd.

Hunts Road LLC

Alta Investments LLC

Super Eight Capital Holding Ltd.

Michael Feigin

Noonan 2006 Revocable Trust

JBCG Enterprises LLC

Alta Investments LLC

FinTekk AP LLC

Robert Dailey

Noonan Family Trust

NUVIEW IRA LLC

ARMAND + L P Della Monica TTEE

Robert Anderson - Equity Trust

Kim Anderson - Equity Trust

The Tim and Tiffany Hodges Revocable Trust

General Pacific

Each investor was given adequate access to sufficient information about us to make an informed investment decision.

None of the securities were sold through an underwriter and accordingly, there were no underwriting discounts or commissions involved.

No registration rights were granted to any of the purchasers.

Issuer Purchases of Equity Securities

Use of proceeds

During the period covered by this Annual Report, we

completed the following transactions in reliance upon exemptions from registration under the Securities Act:

Between October 1, 2025, and March 30, 2026, we

issued 193,968 shares of Series C Convertible Preferred Stock and 371,767 warrants, pursuant to a PIPE offering, for proceeds of $2,676,754.

The proceeds were used for general working capital and operational purposes, including Legal Fees, Accounting and Audit Fees, testing

and certification, and preparation to launch product offerings.

Between October 1, 2025, and March 30, 2026, we

issued 1,563,989 shares of Common Stock, as follows:

220,000 shares pursuant to the acquisition of intellectual property from Breakthrough Chemistry, Inc., valued at $1,775,400.

346,127 shares for the cashless conversion of 359,375 warrants.

500,000 shares for conversion of 150,000 shares of Series C Convertible Preferred Stock.

475,862 shares for conversion of debt and accrued interest of $1,071,821.

55,333 shares for services valued at $443,377.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity